Researchers using tiny fragments of living human brain tissue, obtained as a byproduct of routine shunt surgery, have directly measured how fast two Alzheimer's disease proteins turn over inside the brain, something previously possible only in fixed post-mortem tissue or inferred indirectly from blood and spinal fluid. The study, led by Ross W. Paterson and colleagues and published in Nature Communications on September 24, 2026, analyzed cortical biopsies from 18 people undergoing ventriculoperitoneal shunt surgery for suspected normal pressure hydrocephalus, a fluid buildup condition that sometimes overlaps with older age and cognitive symptoms but is distinct from Alzheimer's disease itself.

Amyloid plaques, the sticky protein clusters long associated with Alzheimer's, were present in 9 of the 18 biopsies, while mature tau tangles were rare across the group. Using mass spectrometry imaging, the team mapped the chemical makeup of the plaques within the tissue and found that phosphorylated tau 217, a form of tau closely tracked in blood tests for Alzheimer's, was concentrated in the tissue immediately surrounding plaques, a spatial pattern consistent with a local relationship between the two proteins. To measure how quickly each protein is replaced, participants received an intravenous tracer that labels newly made proteins; the researchers detected newly labelled tau in the biopsied tissue within about three hours, and used the labelling data to calculate a turnover rate for tau in living brain. Amyloid, measured with the same tracer approach, did not show comparable evidence of rapid new production, a contrast the authors describe as rapid tau turnover set against comparatively stable amyloid plaques.

The approach builds on a smaller pilot by an overlapping team, presented as a scientific abstract in Alzheimer's and Dementia in January 2025, which used six shunt-surgery biopsies and reported that labelled amyloid could not be detected in any of the six samples even as newly made tau appeared within hours, a pattern the new, larger study now extends. The method depends on a rare surgical opportunity, brain tissue removed as part of an operation for a different condition, rather than a study designed around Alzheimer's disease itself, and the authors frame it as a proof of concept for studying early pathology during life rather than a finished picture of how the disease unfolds.